SCHEMBL119526

SCHEMBL119526

ClCc1cc2cc(Br)ccc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.51
CYP2A6 P11509 1/20 0.49
PIM1 P11309 1/20 0.47
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GPR35 Q9HC97 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
MAOA P21397 1/20 0.42
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 4/20 0.41
NPC1 O15118 3/20 0.41
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
MMP2 P08253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16376504 0.82 CYP19A1 (0.53) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL6301307 0.81 CYP19A1 (0.49) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL120819 0.81 IDO1 (0.55) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL6300586 0.81 CYP19A1 (0.51) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL30317998 0.81 CYP19A1 (0.51) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL31095794 0.81 IDO1 (0.55) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL3623465 0.81 LOXL2 (0.58) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL28156013 0.81 CYP19A1 (0.51) CYP19A1CYP2A6PIM1GRIN1GRIN2A
SCHEMBL361904 0.78 CYP19A1 (0.53) CYP19A1GPR35CA12CA1CA2
SCHEMBL29779144 0.78 CYP19A1 (0.53) CYP19A1GPR35CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4691558-A2 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2026-02-11 EP disclosed
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2025-09-25 US disclosed
EP-2857018-B1 Treatment or prophylaxis of proliferative conditions UNIV COURT OF THE UNIV OF DUNDEE (GB) 2025-09-03 EP disclosed
US-20250179055-A1 Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2025-06-05 US disclosed
WO-2025103442-A1 SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-05-22 WO disclosed
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2020-11-19 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2017-12-28 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
CN-102458394-A Treatment or prevention of proliferative conditions UNIV DUNDEE 2012-05-16 CN disclosed
EP-2424524-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2012-03-07 EP disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
WO-2010125350-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-11-04 WO disclosed
WO-2010125350-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS BRCA1, CYP1B1, UGT1A1 CYP19A1 7/4885CYP2A6 82/4885PIM1 4196/4885
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 CYP19A1 7/4885CYP2A6 62/4885PIM1 3207/4885
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 CYP19A1 7/4885CYP2A6 62/4885PIM1 3207/4885
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 CYP19A1 7/4885CYP2A6 62/4885PIM1 3207/4885
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, BRCA1, UGT1A1 CYP19A1 6/4885CYP2A6 81/4885PIM1 3427/4885
US-20250179055-A1 Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof PCSK9, LPL, LYPLA1 CYP19A1 691/4885CYP2A6 1329/4885PIM1 2739/4885
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 CYP19A1 8/4885CYP2A6 88/4885PIM1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.